Recent Progress in Alzheimer's and Parkinson's Diseases

410 Pages·2005·3.94 MB·English

by  Hanin

Prelims Revised 31/3/05 2:50 pm Page i
Recent Progress in Alzheimer’s
and Parkinson’s Diseases
Prelims Revised 31/3/05 2:51 pm Page ii
Her Majesty Queen Sophia of Spain
Prelims Revised 31/3/05 2:51 pm Page iii
Recent Progress in Alzheimer’s
and Parkinson’s Diseases
Edited by
Israel Hanin
PhD
Professor and Chairman Emeritus, Department of Pharmacology and Experimental Therapeutics
Loyola University Medical Center
Maywood, Illinois, USA
Ramón Cacabelos
MD PhD DMSci
President and Chief Executive Officer
EuroEspes, Santa Marta de Babío
La Coruña
Spain
Abraham Fisher
PhD
Senior Scientist
Israel Institute for Biological Research
Ness-Ziona
Israel
LONDON AND NEW YORK
Prelims Revised 31/3/05 2:51 pm Page iv
© 2005 Taylor & Francis, an imprint of the Taylor & Francis Group
First published in the United Kingdom in 2005
by Taylor & Francis,
an imprint of the Taylor & Francis Group,
2 Park Square, Milton Park
Abingdon, Oxon OX14 4RN, UK
Tel.: [phone]
Fax.: [phone]
Website: www.tandf.co.uk
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or trans-
mitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise,
without the prior permission of the publisher or in accordance with the provisions of the Copyright,
Designs and Patents Act 1988 or under the terms of any licence permitting limited copying issued by
the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 0LP.
Although every effort has been made to ensure that all owners of copyright material have been acknowl-
edged in this publication, we would be glad to acknowledge in subsequent reprints or editions any omis-
sions brought to our attention.
British Library Cataloguing in Publication Data
Data available on application
Library of Congress Cataloging-in-Publication Data
Data available on application
ISBN 1-84184-320-2
Distributed in North and South America by
Taylor & Francis
2000 NW Corporate Blvd
Boca Raton, FL 33431, USA
Within Continental USA
Tel.: [phone]; Fax.: [phone]
Outside Continental USA
Tel.: [phone]; Fax.: [phone]
E-mail: [email protected]
Distributed in the rest of the world by
Thomson Publishing Services
Cheriton House
North Way
Andover, Hampshire SP10 5BE, UK
Tel.: [phone]
E-mail: [email protected]
Composition by Parthenon Publishing
Printed and bound by Antony Rowe Ltd., Chippenham, Wiltshire, UK
Prelims Revised 31/3/05 2:51 pm Page v
Contents
List of Contributors ix
Preface xxi
1. Mechanisms of degeneration in Parkinson’s disease 1
B Wolozin, M Frasier, H Snyder, P Choi, N Golts
2. Underlying biochemical and molecular mechanisms of dyskinesia 9
H Reichmann, P Riederer
3. Molecular neuropathology of parkinsonism 19
DW Dickson
4. Familial parkinsonian mutations affect the ability of catecholaminergic neurons to 27
withstand proteasome inhibition
MR Cookson
5. Acetylcholinesterase, cholinergic signaling and Parkinson’s disease 33
Y Ben-Shaul, H Bergman, H Soreq
6. Bone marrow stem cells: possible source for cell therapy in Parkinson’s disease 45
YS Levy, S Bulvik, A Burshtein, Y Barhum, E Melamed, D Offen
7. Insulin-like growth factor I and intracellular signal transduction pathways 53
in aging and dementia
W-H Zheng, R Quirion
8. The interrelationships between gait and cognitive function 61
N Giladi, PL Sheridan, JM Hausdorff
9. Advances in gene transfer and pharmacological regulation of protein aggregation 69
in the treatment of Alzheimer’s and Parkinson’s diseases
P Bar-On, E Rockenstein, M Hashimoto, E Masliah
v
Prelims Revised 31/3/05 2:51 pm Page vi
Recent Progress in Alzheimer’s and Parkinson’s Diseases
10. α- andβ-Synucleins: two parent proteins that display similar anti-apoptotic 81
phenotypes but distinct responses to 6-hydroxydopamine-induced toxicity
F Checler, C Alves da Costa
11. Functional genomics and pharmacogenetics in Alzheimer’s disease 89
R Cacabelos, Y Kubota, C Isaza, J Henao, L Fernández-Novoa, VRM Lombardi,
L Corzo, V Pichel
12. The genetics of tau and neurodegenerative disease 103
BKraemer, I D’Souza, GD Schellenberg
13. Amyloid plaques and neurofibrillary tangles in a triple transgenic model: qualitative 111
similarities with human Alzheimer’s neuropathology
S Oddo, FM LaFerla
14. Apolipoprotein E and Alzheimer’s disease: what has a decade told us? 117
KA Crutcher
15. Comparison of the effects of apolipoprotein E4 on presynaptic and cytoskeletal 127
plasticity following environmental stimulation
O Levi, DM Michaelson
16. Cholesterol and the Aβ cascade: pathological implication of apolipoprotein E 133
in Alzheimer’s disease
K Yanagisawa
17. Brain inflammation and psychogeriatric diseases 139
H Akiyama, H Uchikado
18. Neuroinflammatory mechanisms are involved in the early steps of the pathological 145
cascade in Alzheimer’s disease
P Eikelenboom, JJM Hoozemans, JM Rozemuller, R Veerhuis, WA van Gool
19. Vascular nitric oxide: a key molecule in Alzheimer’s disease pathogenesis 153
JC de la Torre
20. Alzheimer pathology and endoplasmic reticulum stress 161
T Kudo, T Katayama, K Imaizumi, D Kanayama, J Hitomi, M Okochi, M Tohyama,
M Takeda
21. Molecular mechanism of amyloid β-peptide-induced impairment of neurotransmission 167
and memory in relation to oxidative stress
K Yamada, H-C Kim, T Nabeshima
22. Regulating factors for microglial activation: implication for Alzheimer’s disease and 171
brain damage
VRM Lombardi, L Fernández-Novoa, I Etcheverría, S Seoane, R Cacabelos
23. Cerebrospinal fluid phosphorylated tau protein at serine 199 is a useful diagnostic 177
biomarker in Alzheimer’s disease and mild cognitive impairment
K Urakami, H Arai, N Itoh, K Ishiguro, H Oono, M Taniguchi, K Wada-Isoe, Y Wakutani,
S Kuzuhara, H Sasaki, K Nakashima, K Imahori
vi
Prelims Revised 31/3/05 2:51 pm Page vii
Contents
24. Stem cell strategies for Alzheimer’s disease 183
K Sugaya
25. Can mild cognitive impairment predict Alzheimer’s disease? 191
H Soininen, S Tuomainen, C Pennanen, T Hänninen, M Kivipelto
26. Water quality and cholesterol-induced pathology: differential effects of the M-1 197
muscarinic receptor agonist AF267B on accumulation of Alzheimer-like amyloid β
in rabbit brain
DL Sparks, J Lochhead, A Fisher, T Martin
27. Lack of effect of certoparin in P301L mutant tau pathology 205
M Walzer, M Hejna, S Lorens, J Lee
28. Heparin-derived oligosaccharides as potential therapeutic agents in senile dementia 211
and stroke
Q Ma, I Hanin, U Cornelli, J Lee, O Iqbal, J Fareed
29. Glycosaminoglycans and neuroprotection: effect on cholinergic neurodegeneration 227
B Dudas, M Rose, U Cornelli, L De Ambrosi, M Cornelli, I Hanin
30. Orchestration of the functional subsites in the acetylcholinesterase active center – 235
contribution to catalytic perfection and high reactivity toward specific ligands
A Shafferman, D Barak, A Ordentlich, N Ariel, C Kronman, D Kaplan, B Velan
31. Altered glycosylation of acetylcholinesterase in the Alzheimer’s disease brain: 243
involvement of α7 nicotinic acetylcholine receptors
DH Small, LR Fodero, J Sáez-Valero
32. Cholinotrophic alterations in individuals with mild cognitive impairment and 249
Alzheimer’s disease
EJ Mufson, M Fahnestock, JH Kordower, ST DeKosky
33. Pharmacological properties of TV3326, a cholinesterase and brain selective 257
monoamine oxidase inhibitor for the treatment of dementia co-morbid with depression
M Weinstock, MBH Youdim
34. Physostigmine and its analog phenserine have different effects on Alzheimer 261
amyloid-β precursor protein
DK Lahiri, GM Alley, MR Farlow, JT Rogers, NH Greig
35. Translation and processing of amyloid precursor protein (APP) by an M1 muscarinic 267
agonist and an acetylcholinesterase inhibitor: the role of APP mRNA5′-untranslated
region sequences
JT Rogers, NH Greig, DK Lahiri, A Fisher
36. Modulation of Alzheimer’s amyloidosis by statins: possible mechanisms of action 279
S Petanceska, M Pappolla, LM Refolo
37. β-secretase – progress and questions 291
M Citron
vii
Prelims Revised 31/3/05 2:51 pm Page viii
Recent Progress in Alzheimer’s and Parkinson’s Disease
38. Tau phosphorylation and assembly in tauopathies 297
J Avila, M Pérez, A Gómez-Ramos, JJ Lucas, F Hernández
39. Alzheimer’s disease: a true tauopathy fueled by amyloid precursor protein dysfunction 301
A Delacourte
40. Neurofibrillary degeneration: a promising target for the treatment of Alzheimer’s 309
disease and other tauopathies
K Iqbal, A del C Alonso, E El-Akkad, C-X Gong, N Haque, S Khatoon, H Tanimukai,
I Tsujio, I Grundke-Iqbal
41. Neuropathology and tau 317
KA Jellinger
42. Conformational analysis of tau and tau aggregates by fluorescence spectroscopy 329
M von Bergen, L Li, E-M Mandelkow, E Mandelkow
43. Transglutaminase-catalyzed cross-linking of tau in Alzheimer’s disease and 339
progressive supranuclear palsy
NA Muma, RA Halverson
44. The impact of extracellular amyloid-β (Αβ) peptides on cortical neurotransmitters and 347
of intracellular Aβ accumulation on protein expression
AC Cuello, KFS Bell, V Echeverria, E Lopez, A Ribeiro-da-Silva, M Szyf
45. Activation of Wntsignaling protects from amyloid-β-peptide neurotoxicity 355
NC Inestrosa, MS Urra, J Scheu, GG Farias, A Fisher, M Bronfman, RA Fuentealba
46. Human prion diseases 363
T Pan, R Li, B-S Wong, S-C Kang, P Gambetti, M-S Sy
Index 371
viii
Prelims Revised 31/3/05 2:51 pm Page ix
List of contributors
H AkiyamaMD PhD J AvilaPhD
Tokyo Institute of Psychiatry Centro de Biología Molecular “Severo Ochoa”
Department of Psychogeriatrics Facultad de Ciencias
2-1-8 Kamikitazawa Campus de Cantoblanco
Setagaya-ku Universidad Autónoma de Madrid
Tokyo 156-8585 28049 Madrid
Japan Spain
GM AlleyBS D Barak
Department of Psychiatry and Neurology Department of Organic Chemistry
Institute of Psychiatric Research Israel Institute for Biological Research
Indiana University School of Medicine Ness-Ziona 74100
791 Union Drive, Rm PR-313 Israel
Indianapolis, IN 46202-4887
P Bar-On
USA
Department of Neurosciences
C Alves da CostaPhD University of California
Institut de Pharmacologie Moléculaire et Cellulaire San Diego
UMR6097 CNRS/UNSA La Jolla, CA 92093-0624
660 Route des Lucioles USA
06560 Valbonne
Y BarhumMSc
France
Laboratory of Neuroscience
H AraiMD PhD Felsenstein Medical Research Center and
Department of Geriatrics Department of Neurology
Tohoku University School of Medicine Rabin Medical Center
Sendai 980-8578 Beilinson Campus
Japan Tel Aviv University
Sackler School of Medicine
N Ariel
Petah-Tikva 49100
Department of Biochemistry and Molecular Genetics
Israel
Israel Institute for Biological Research
Ness-Ziona 74100
Israel
ix